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A substantial proportion of the burden of depression arises from its recurrent nature. The risk of relapse after antidepres-
sant medication (ADM) discontinuation is high but not uniform. Predictors of individual relapse risk after antidepressant
discontinuation could help to guide treatment and mitigate the long-term course of depression. We conducted a system-
atic literature search in PubMed to identify relapse predictors using the search terms ‘(depress* OR MDD*) AND
(relapse* OR recurren*) AND (predict* OR risk) AND (discontinu* OR withdraw* OR maintenance OR maintain or con-
tinu*) AND (antidepress* OR medication OR drug)’ for published studies until November 2014. Studies investigating
predictors of relapse in patients aged between 18 and 65 years with a main diagnosis of major depressive disorder
(MDD), who remitted from a depressive episode while treated with ADM and were followed up for at least 6 months
to assess relapse after part of the sample discontinued their ADM, were included in the review. Although relevant in-
formation is present in many studies, only 13 studies based on nine separate samples investigated predictors for relapse
after ADM discontinuation. There are multiple promising predictors, including markers of true treatment response and
the number of prior episodes. However, the existing evidence is weak and there are no established, validated markers of
individual relapse risk after antidepressant cessation. There is little evidence to guide discontinuation decisions in an
individualized manner beyond overall recurrence risk. Thus, there is a pressing need to investigate neurobiological mar-
kers of individual relapse risk, focusing on treatment discontinuation.
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Introduction
Depression is a major health issue (Whiteford et al.
2013), and a substantial proportion of its burden arises
through relapses and chronic courses: more than half
of those with a ﬁrst episode of depression will go on
to have a second, and the majority of them will have
further episodes (American Psychiatric Association,
2000). Preventing relapses of depression is hence a crit-
ical component of treatment. Antidepressant medica-
tions (ADM) have proven utility not only in treating
acute episodes of depression, but also in reducing the
risk of relapse (Geddes et al. 2003; Kaymaz et al.
2008; Glue et al. 2010; Sim et al. 2015). However, they
are no panacea: not all patients respond to ADMs, par-
ticularly not ﬁrst-line ones (e.g. Rush et al. 2006); many
experience side-effects; thus, discontinue treatment
rapidly (Olfson et al. 2006) or adhere partially (Hunot
et al. 2007); some relapse despite ADM maintenance
treatment while others do not relapse despite discon-
tinuation. Of note, there are also suggestions that anti-
depressant treatment itself might contribute to relapses
after discontinuation through perturbational effects on
neuromodulatory systems (Andrews et al. 2011).
A substantial effort is now underway to improve
acute treatment response rates by improving how
agents are targeted to individual patients (e.g.
ISPOT-D; CAN-BIND; IMAGEMEND), with some
promising initial results (e.g. Palmer, 2015). However,
the other side of the treatment, the decision about
whether to move to (possibly long-term) maintenance
therapy or to discontinue, has attracted far less re-
search focused on making individualized predictions.
Given the importance of the initial episodes of depres-
sion in setting up the long-term course of the disorder
(e.g. Kendler et al. 2000; Monroe & Harkness, 2005,
2011), this is a very pressing research lacuna.
Guidelines [National Collaborating Centre for
Mental Health (UK), 2010; Bauer et al. 2013] currently
recommend a continuation of treatment after an initial
response for 4 to 9 months and maintenance treatment
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of 2 years or longer in the case of recurrent major de-
pressive disorder (MDD). As such, the main indices
that are used to inform the termination of maintenance
treatment are the treatment duration and the number
of prior episodes or chronicity. Though these recom-
mendations are well motivated by the natural course
of depressive episodes (Frank et al. 1991; Kessler et al.
2003) and the protective effect of antidepressants, to
our knowledge there are no systematic examinations
of what predictors relate to discontinuation above
and beyond overall relapse risk. We hence here aim
to provide a systematic review of the existing evidence.
Overall relapse risk and relapse risk after discontinu-
ation may be only partially related: some patients will
relapse independently of whether they are prescribed
any medication. Notably, although such high-risk
patients are typically prime targets for treatment,
they would derive as little advantage from the medica-
tion as those who will not relapse either way.
Hence, it is critical to establish predictors of the re-
lapse risk for individual patients. In terms of clinical
guidance, this raises two related questions. The ﬁrst
asks what the individual’s relapse risk would be after
discontinuation. Patients who have a very low risk of
relapse after discontinuation have less scope for ben-
eﬁting from further treatment (grey lines, Fig. 1a)
than those with high risk (black lines, Fig. 1a). This
requires putative predictive variables to differentiate
between relapsers and non-relapsers speciﬁcally after
discontinuation. To establish, second and more gener-
ally, what the beneﬁt of continued treatment in a par-
ticular patient is, the relapse risk after discontinuation
has to be compared with the relapse risk under contin-
ued medication and thus requires examination of
interactions, comparing the difference between relap-
sers and non-relapsers in continuation and discontinu-
ation arms (Fig. 1b). We examined both of these, i.e.
searched for studies that either reported a difference
Fig. 1. Relapse risk after placebo-controlled randomized antidepressant treatment discontinuation. Some risk factors may
identify patients who beneﬁt from antidepressant medication due to effects driven by discontinuation (a), or continuation
arms (c). In the former case, the risk score should differ between relapsers and non-relapsers in the discontinuation arm (b),
while in the latter case it should differ in the continuation arm (d). Other risk factors may identify mixed effects.
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between relapsers and non-relapsers speciﬁcally after
discontinuation; or an interaction of treatment (con-
tinuation/discontinuation) with a putative predictor
in differentiating relapsers and non-relapsers. That is,
we were particularly interested in whether there was
a treatment × predictor interaction between relapsers
and non-relapsers. Note, however, that an interaction
can be driven by the continuation arm alone, too,
and thereby be relatively uninformative about discon-
tinuation (Fig. 1c, d).
Method
We conducted a systematic literature search in
PubMed to identify relapse predictors using the search
terms ‘(depress* OR MDD*) AND (relapse* OR recur-
ren*) AND (predict* OR risk) AND (discontinu* OR
withdraw* OR maintenance OR maintain or continu*)
AND (antidepress* OR medication OR drug)’ for pub-
lished studies until November 2014. The search
resulted in 899 retrieved studies.
Inclusion criteria were:
(a) Patient population aged between 18 and 65 years;
(b) Main diagnosis of MDD;
(c) Remitted from a depressive episode while treated
with ADM;
(d) Follow-up of at least 6 months to assess relapse;
(e) Part of the samplediscontinued theADM(discontinu-
ation could either be part of a randomized controlled
design, whereby part of the sample received placebo
after randomization starting at a predeﬁned point in
time or based on the decision of the patient and treat-
ing physician as part of a naturalistic design);
(f) Original research paper;
(g) Reported relapse predictors either in the discontinu-
ation group alone; or reported interaction of treat-
ment × putative predictor in predicting relapse.
Exclusion criteria were:
(a) Anonymous data derived from health systems pre-
scription records;
(b) Confounds with psychotherapy.
I.M.B. and Q.J.M.H. ﬁrst screened all titles. Abstracts of
all titles judged potentially relevant by either author
were then judged on inclusion criteria a–f and exclu-
sion criteria. The resulting 61 papers were then
retrieved in full text and inclusion and exclusion cri-
teria examined by I.M.B. (including, in addition, criter-
ion g) and unclear cases discussed jointly. Authors of
individual studies were not contacted.
Of note, the natural course of depressive episodes
suggests that re-emergence of symptoms within 6–9
months might be due to relapses into the index episode
while thereafter they indicate a new episode (Frank
et al. 1991). We will here refer to both as relapses as
there are insufﬁcient data to distinguish relapses
from recurrences for the present purpose.
Results
Overall, 899 studies were retrieved. Cohen’s κ for inter-
rater agreement for abstracts was 0.75. A total of 61 po-
tentially relevant papers (Fig. 2) were identiﬁed. After
reading the full-text versions of all these, 13 studies
based on nine separate datasets (Table 1) were identiﬁed
as suitable and included. No study used neuroimaging
predictors. Predictors in the categories demographics,
disease course, depression subtype and co-morbidity
were investigated. An overview of the investigated pre-
dictors is shown in Tables 2 and 3. No naturalistic study
was identiﬁed. All patients who discontinued received
placebo treatment. Henceforth, treatment × characteristic
interactions always refer to interactions in the prediction
of relapse unless otherwise speciﬁed.
Demographics
Age and gender
The interaction of both age and gender with treatment
(switch to placebo v. continuing ADM) failed to reach
Fig. 2. Consolidated Standards of Reporting Trials
(CONSORT) diagram depicting number of studies excluded
at each step. Exclusion and inclusion criteria are not
mutually exclusive. Not all criteria met by each study might
be listed in the second box on the right-hand side, since it
was not always possible to determine all criteria from the
abstract.
428 I. M. Berwian et al.
https://doi.org/10.1017/S0033291716002580
Downloaded from https:/www.cambridge.org/core. ETH-Bibliothek, on 24 Feb 2017 at 10:30:28, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
Table 1. Description of datasets
Original
datasets
Studies investigated
predictors
Diagnostic
criteria
Pre-randomization
period, weeks
Number of patients per
group Criteria for relapse
Length of
follow-up,
weeks Medication
McGrath et al.
(2006)
McGrath et al. (2006),
Yang et al. (2009),
Iovieno et al. (2011),
Trinh et al. (2011)
DSM-IV 12 Fluoxetine = 131,
placebo = 131
Two consecutive weeks of ratings of
less than ‘much improved’ on the
CGI improvement scale compared
with ratings at entry into the study
52 Fluoxetine
Hochstrasser
et al. (2001)
Hochstrasser et al.
(2001)
DSM-IV and
MADRS
11 to 25 Citalopram = 132 (20 mg: 53,
40 mg: 66, 60 mg: 13),
placebo= 132
MADRS total score5 22, conﬁrmed
after 3–7 days
48 to 77 Citalopram
Keller et al.
(1998)a
Keller et al. (1998)a DSM-III-R and
HAM-D
28 Sertraline = 77, placebo = 84 DSM-III-R criteria for MDD for at least
3 weeks, CGI severity score5 4, CGI
improvement score5 3, and an
increase in HAM-D to54 points
higher than the maintenance phase
baseline, conﬁrmed within 1 week
and by senior clinician
76 Sertraline
Stewart et al.
(1998)
Stewart et al. (1998),
McGrath et al. (2000),
Joliat et al. (2004)
DSM-III-R and
modiﬁed
HAM-D
12/26/50 Fluoxetine hydrochloride =
96 (until week 26), 99 (until
week 50), 102 (until week
62), placebo = 95 (starting
week 12)
Either a modiﬁed HAM-D score5 14
for 3 consecutive weeks or having
met the DSM-III-R criteria for MDD
for 2 consecutive weeks
50 Fluoxetine
Keller et al.
(2007)
PREVENT
study
Kornstein et al. (2014) DSM-IV and
HAM-D
34 First 12 months:
venlafaxine = 129,
placebo = 129; second 12
months: venlafaxine = 32,
placebo = 40
HAM-D-17 score > 12 and an
HAM-D-17 reduction from
acute-phase baseline that was not
more than 50% at two consecutive
visits or at the last valid visit prior to
patient discontinuation
52 to 104 Venlafaxine
Perahia et al.
(2006)
Fava et al. (2009) DSM-IV,
HAM-D-17 and
CGI-S
12 Duloxetine = 136,
placebo = 142
Increase in the CGI-S score of52
points compared with
randomization and meeting the
MINI depression module criteria for
major depressive episode at two
consecutive visits at least 2 weeks
apart
26 Duloxetine
Thase et al.
(2001)
Nierenberg et al.
(2004)
DSM-IV and
HAM-D-17
8 to 12 Mirtazapine = 76,
placebo = 80
Clinician’s decision 40 Mirtazapine
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signiﬁcance in three studies (Hochstrasser et al. 2001;
McGrath et al. 2006; Fava et al. 2009). Gender × treat-
ment interactions failed to reach signiﬁcance in two
further studies (McGrath et al. 2000; Kornstein et al.
2014). The latter re-examined data from the
Prevention of Recurrent Episodes of Depression With
Venlafaxine for Two Years (PREVENT) trial dataset
where patients were randomized between placebo
and venlafaxine maintenance after either 6 or 18
months. The interaction of gender with treatment
failed to reach signiﬁcance at either randomization
point.
Race and ethnicity
One study investigated the effect of race and ethnicity
(Trinh et al. 2011). Race and ethnicity had no effect on
time to relapse in either continuation and discontinu-
ation arms examined separately. Of note, although
the discontinuation effect was signiﬁcant in the
Caucasian group (p = 0.001), there was no discontinu-
ation effect in the minority groups. However, power
in these groups was low (214 Caucasian patients v.
22, 13 and six African American, Latino American
and Asian Americans, respectively).
Disease course
Chronicity and age of onset
None of the four studies examining chronicity and age
of onset found a signiﬁcant interaction with treatment
(McGrath et al. 2000, 2006; Hochstrasser et al. 2001;
Fava et al. 2009). Of note, these studies explored differ-
ent deﬁnitions of chronicity, e.g. a last episode length
>2 years (McGrath et al. 2000) or having very rare or
no remission (McGrath et al. 2006).
Number of prior episodes
Four studies have investigated the interaction of num-
ber of prior episodes and treatment. No signiﬁcant
results were reported (Keller et al. 1998; McGrath
et al. 2000; Hochstrasser et al. 2001; Fava et al. 2009).
Of note, in the study by Keller et al. (1998) the risk of
re-emergence of depression during placebo treatment
among patients experiencing their ﬁrst episode was
lower (40%) than in patients with recurrent disorder
(55%). By contrast, sertraline was equally effective for
patients in these subgroups (29% v. 24% symptom re-
emergence). Although the drug–placebo difference in
prophylactic efﬁcacy was higher for patients with re-
current depression (i.e. 31% v. 11%), the treatment ×
prior episode events interaction analysis did not sign-
iﬁcantly predict time to re-emergence (p = 0.25), pos-
sibly due to power issues (see also the discussion of
meta-analytic results in the Discussion).Ta
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Table 2. Demographics, disease course variables, depression subtypes and co-morbidity
McGrath
et al. (2000)
Trinh
et al.
(2011)
Hochstrasser
et al. (2001)
McGrath
et al. (2006)
Kornstein
et al. (2014)
Fava
et al.
(2009)
Keller
et al.
(1998)
Stewart
et al.
(1998)
Yang
et al.
(2009)
Nierenberg
et al. (2004)
Iovieno
et al.
(2011)
Rouillon
et al. (2000)
Joliat
et al.
(2004)
Demographics
Age N.S. N.S. N.S.
Gender N.S. N.S. N.S. N.S. N.S.
Race and
ethnicity
Sig
Disease course
variables
Chronicity and
age of onset
N.S. N.S. N.S.
Severity at
onset
N.S. N.S.
Number of
prior episodes
N.S. N.S. N.S. N.S.
Response
pattern
N.S. Sig Sig
Residual
symptoms
N.S. N.S. N.S. N.S.
Speciﬁc
residual
symptoms:
Phobic anxiety N.S.
Depression
subtypes
Typical v.
atypical
depression
Siga N.S.
Melancholic
subtype
Sig N.S.
Double
depression
N.S.
Bipolar II N.S.
Co-morbidity
Anxiety N.S. Sig
Somatic pain Sig
N.S., No signiﬁcant interaction term of treatment and predictor or signiﬁcant subgroup comparisons were reported; Sig, either signiﬁcant interaction term of treatment and predictor
or signiﬁcant subgroup comparisons were reported.
a Three-way interaction of treatment, neurovegetative symptoms and response pattern was signiﬁcant.
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Severity at onset and episode length
Only two studies report examining an interaction of se-
verity at onset with treatment, both failing to reach
signiﬁcance (Keller et al. 1998; Hochstrasser et al.
2001). One study found no interaction with episode
length (Fava et al. 2009).
True drug response v. placebo response pattern
A pattern of delayed but sustained improvement after
antidepressant treatment initiation may distinguish
improvements driven by a truly pharmacological effect
from those driven by a placebo effect (Quitkin et al.
1987). Three studies have examined whether this
might in turn predict differential relapse risk after dis-
continuation. Two studies found consistent subgroup
effects, whereby discontinuation increased relapse
rates in the likely true drug responders [Nierenberg
et al. 2004: log-rank = 8.55, degrees of freedom (df) = 1,
p = 0.003; Stewart et al. 1998: log-rank = 22.37; p < 0.001
when discontinuing after 12 v. 26 weeks; log-rank
test score = 8.23; df = 1; p < 0.005 when discontinuing
after 26 v. 50 weeks]. The difference between placebo
and continuation groups in patients with initial
placebo response patterns was not signiﬁcant.
Nierenberg et al. (2004) also found that the relapse
risk after discontinuation was larger in patients with
true than placebo response patterns (log-rank = 4.87,
df = 1, p = 0.027). Though these results are suggestive,
neither study explicitly tested for interactions.
McGrath et al. (2006) failed to ﬁnd a signiﬁcant inter-
action between response pattern and discontinuation.
McGrath et al. (2000) extended the Stewart et al.
(1998) ﬁndings (see below).
Residual symptoms at randomization
Residual symptoms, i.e. subthreshold symptoms pre-
sent at the time of randomization, failed to interact
with treatment in four studies (Keller et al. 1998;
Rouillon et al. 2000; McGrath et al. 2006; Fava et al.
2009) though Rouillon et al. (2000) report a trend
(p = 0.06) after milnacipram discontinuation. Analyses
in a further study investigating speciﬁc residual symp-
toms, namely phobic anxiety, also failed to yield sign-
iﬁcant results (Yang et al. 2009).
The lack of interaction with treatment holds for both
true residual symptoms (present both at treatment ini-
tiation and randomization) and symptoms emerging
with treatment (not present at treatment initiation;
Iovieno et al. 2011).
Depression subtypes
Typical v. atypical depression
Neurovegetative symptoms moderated an effect of
treatment response speciﬁcity (McGrath et al. 2000;
see also below for response speciﬁcity). Amongst
patients with typical vegetative symptoms who
appeared to have responded speciﬁcally to the treat-
ment (a slow, sustained response after treatment
onset), there was a large effect of discontinuation
(drug–placebo difference; log-rank = 38.8, df = 3,
p = 1.9 × 10−8). This effect was absent in patients with
a non-speciﬁc response to treatment and in those
with atypical vegetative symptoms. The interaction of
treatment and neurovegetative symptoms alone was
not reported by McGrath et al. (2000) and was not sign-
iﬁcant in a later trial by the same authors (McGrath
et al. 2006).
Melancholic subtype
Two studies investigated the interaction between melan-
cholic depression subtype and treatment. In McGrath
et al. (2000), patients with melancholic MDD
(Diagnostic and Statistical Manual of Mental Disorders,
Third Edition Revised; DSM-III-R) appeared to show a
larger drug–placebo difference than those with non-
melancholic MDD due to increased survival in the mel-
ancholic group assigned to maintenance ﬂuoxetine (log
rank = 29.3, df = 3, p = 1.9 × 10−6). However, no inter-
action was reported and the effect did not survive
when controlling for neurovegetative pattern (typical v.
atypical), even though melancholic and neurovegetative
patterns were uncorrelated. Melancholic subtype did not
interact signiﬁcantly with treatment in the study by
McGrath et al. (2006).
Double depression and bipolar II
Neither presence of dysthymia nor a past history of
hypomanic symptoms interacted with treatment
(Keller et al. 1998; McGrath et al. 2000). However,
Keller et al. (1998) only included patients with chronic
or double depression and no studies exist that have
Table 3. Further predictors only investigated once
Predictor Study
Interaction with
treatment
Menopausal status Kornstein et al.
(2014)
N.S.
Treatment by general
practitioner
Hochstrasser
et al. (2001)
N.S.
Citalopram dose and
concomitant
treatment
Hochstrasser
et al. (2001)
N.S.
N.S., Non-signiﬁcant.
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compared dysthymia and recurrent depression with
recurrent depression alone.
Co-morbidity
Two studies examined the effect of anxiety. Joliat et al.
(2004) investigated drug- v. placebo-treated groups
separately. High anxiety increased relapse risk in the
discontinuation group (risk ratio = 1.632, p = 0.013),
but not in the continuation group, though no inter-
action was reported. Relapse rates were 28.5% v.
27.2% and 53.3% v. 40.7% for continuation and discon-
tinuation groups with high and low anxiety, respect-
ively. Fava et al. (2009) found the interaction of
treatment and Hamilton Rating Scale for Depression
anxiety/somatization subscore as categorical variable
not to be signiﬁcant.
Somatic pain ratings were found to interact signiﬁ-
cant with treatment in one study on duloxetine (Fava
et al. 2009; hazard ratios 0.62 v. 0.25 in high- v. low-
pain groups, p = 0.048).
Other variables
Other variables investigated only once and not found
to interact with treatment are presented in Table 3.
Discussion
Many of the factors reported on here appear to have
robust properties as predictors of relapse or recurrence
risk independent of medication discontinuation: num-
ber of previous episodes (Berlanga et al. 1999; Kendler
et al. 2000; Burcusa & Iacono, 2007; Hardeveld et al.
2010), residual symptoms (Hardeveld et al. 2010;
Nierenberg et al. 2010) and other factors all robustly in-
crease the risk of relapse. Clearly, individuals with a
higher risk have more potential to beneﬁt from main-
tenance treatment compared with those with little
risk. The presence of such factors, combined with the
known strong protective effect of ADM against relapse,
is therefore a motivating factor for clinicians and
patients alike to continue medications.
However, the relevant question for the individual pa-
tient really is about the differential impact of medication:
will this particular person beneﬁt from continuing treat-
ment? This requires understanding and predicting not
just overall relapse risk, but the speciﬁc consequences
of medication discontinuation, i.e. effects within the sep-
arate arms. Although people with a high risk of relapse
have more scope to beneﬁt from maintenance treatment,
they may still not respond and therefore not beneﬁt. In
addition, discontinuation itself is likely to have an effect
on relapse, indicated by the increased risk in the early
months following discontinuation, which is independent
of length of prior treatment (Viguera et al. 1998). Hence,
there is no necessary overlap between predictors of re-
lapse independent of treatment (relapse risk overall)
and predictors of relapse after antidepressant discon-
tinuation, and we therefore focused on predictors of re-
lapse after discontinuation and the interaction of
treatment with a putative predictor in predicting relapse.
Strikingly, our systematic review identiﬁed only 13
studies examining the latter, based on only nine data-
sets. This is thus very poorly understood even though
data relevant to this question are routinely available in
studies examining continuation and maintenance treat-
ment of depression.
Overall, the state of the ﬁeld is insufﬁcient to draw
either positive or negative conclusions. Nevertheless,
a few ﬁndings are noteworthy. First, guidelines typic-
ally recommend continuation treatment for around
4–9 months (Bauer et al. 2013) after the ﬁrst episode,
and longer thereafter. The studies examined here had
pre-randomization treatment intervals that were most-
ly shorter. Amongst those with varying pre-
randomization durations none examined the impact
of treatment duration directly, meaning that there is
a lack of evidence speaking to this point. Several
meta-analyses (Viguera et al. 1998; Geddes et al. 2003;
Kaymaz et al. 2008; Glue et al. 2010; Andrews et al.
2011) have, however, examined it, with none ﬁnding
a signiﬁcant effect. A newer meta-analysis found an ex-
ponential decrease in relapse risk with increasing treat-
ment length (Baldessarini et al. 2015). However, this
study did not compare discontinuation with mainten-
ance and hence it is unclear how this relates to the dis-
continuation itself. Furthermore, it is unclear whether
the important variable is the time in remission or the
time on medication. These are likely to be particularly
highly correlated in the studies with shorter initial sta-
bilization which Baldessarini et al. (2015) found to have
a higher relapse rate. Furthermore, a meta-analysis by
the same group (Sim et al. 2015) found an increase in
the drug–placebo difference with longer pre-
randomization stabilization time, a result pointing in
the opposite direction. Until more consistent results
are available, discontinuation choices should not be
determined by considerations of treatment duration
alone.
Second, the reviewed studies individually failed to
show clear effects of prior episode number. Two
meta-analyses have addressed this, with discrepant
results. While Viguera et al. (1998) found that patients
with more prior episodes beneﬁted more from anti-
depressant treatment, Kaymaz et al. (2008) came to
the diametrically opposed conclusion, ﬁnding that an
increasing number of prior episodes instead reduced
the prophylactic effect of antidepressants. Using a
meta-regression approach, they later found that the
odds ratio for relapse after discontinuation compared
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with continuation in ﬁrst-episode patients was 0.12,
while it was 0.31 in patients in their second or more
episodes. Furthermore, Sim et al. (2015) found no effect
of the estimated number of prior episodes on the drug–
placebo effect in continuation and long-term studies.
Hence, for patients with multiple past episodes, the
situation is unclear: individual studies do not provide
a clear picture; and meta-analyses raise the possibility
of increased and decreased beneﬁt or no effect at all.
Third, the studies have also not provided clear sup-
port for the inﬂuence of residual symptoms. This is
again surprising. Residual symptom load affects re-
lapse risk overall (Nierenberg et al. 2010) and probably
accounts for the impact of different deﬁnitions of re-
mission on relapse risk (Dunlop et al. 2012). Given
that patients with high relapse risk should stand
more to gain from medication; and given the strong
impact on relapse (Geddes et al. 2003), one would
have expected substantial effects here. It is not incon-
ceivable that placebo treatment response might con-
tribute to this lack of anticipated effects and this
would bring attempts to clearly deﬁne active treatment
response into renewed consideration (Stewart et al.
1998; McGrath et al. 2000; Nierenberg et al. 2004).
The studies byStewart et al. (1998) andNierenberg et al.
(2004) both showed that patients with a ‘true-drug re-
sponse’ with maintained but somewhat delayed im-
provement proﬁted from active treatment compared
with placebo, whereas this difference was not evident in
patients with a ‘placebo response pattern’ with very fast
initial response thatwaspoorlymaintained.While others
have argued for a rapid response overall (Szegedi et al.
2009), this raises the question of whether aspects of the
initial treatment response might differentiate those sub-
jects who do and do not relapse after discontinuation;
and this in turn might provide a particularly powerful
handle on the identiﬁcation of true drug response.
Methodologically, to establish the effect of risk re-
duction after discontinuation of a certain predictor
and whether a subgroup identiﬁed by the predictor
would not beneﬁt from continuous ADM treatment,
one would ideally ﬁrst compute the signiﬁcance level
of the interaction of treatment and predictor and,
only if signiﬁcance is reached, do post-hoc comparisons
between subgroups correcting for multiple compari-
sons to identify subgroup difference that gave rise to
the signiﬁcant interaction term. Few studies followed
this approach, typically either not reporting the inter-
action term, or, if the interaction term is reported to
be signiﬁcant, not doing sufﬁcient post-hoc compari-
sons to establish what gave rise to the signiﬁcant inter-
action term. Furthermore, corrections for multiple
comparisons were not consistently reported.
One possibility for the lack of signiﬁcant ﬁndings is
that antidepressant discontinuation has a far stronger
effect on relapse rates than any other variable, and
that only very large studies or meta/mega-analyses
could identify the smaller moderating factors. The
strength of the effects for instance of number of prior
episodes reported in two meta-analyses (Viguera
et al. 1998; Kaymaz et al. 2008) would seem to speak
against this, but the fact that the sign of their ﬁnding
is in the opposite direction might support the conten-
tion. In this vein, there are also experimental reasons
for small effect sizes. For instance, antidepressant–pla-
cebo response differences have decreased over the past
few decades, in part due to recruitment of less severely
ill patients into trials (Khan et al. 2010). Less ill patients
are known to have a smaller relapse risk overall (e.g.
Nierenberg et al. 2010), and hence are overall less likely
a priori to beneﬁt from continuation treatment. If treat-
ments are encapsulated, blinding may be partially bro-
ken if capsules are intentionally or unintentionally
opened and the true drug/placebo identiﬁed. This
may artiﬁcially increase drug–placebo relapse rates
and thereby reduce the impact of moderators.
Andrews et al. (2011) identiﬁed two further aspects
that may moderate the inﬂuence of risk factors. First,
they found that relapse risk was higher after discon-
tinuing antidepressants with larger effects on the sero-
tonergic or noradrenergic system. Since most studies in
this review used selective serotonin reuptake inhibitors
(SSRIs) or serotonin and norepinephrine reuptake inhi-
bitors (SNRIs), the effect on the serotonergic system
was likely to be high, potentially decreasing the inﬂu-
ence of moderating effects. Second, they suggested the
development of oppositional tolerance in response to
prolonged drug treatment such as the reduction of in-
trinsic serotonin synthesis due to antidepressant-
induced increases in availability. This could contribute
to increased relapse risks after prolonged treatment
and thereby counterbalance protective effects of longer
treatment.
The present systematic review has some limitations.
First, since we only used one database for our search
and the database had not access to the full text of all
relevant studies for the search, it is possible that we
missed eligible studies. There may also be a positive
bias due to reporting biases, as positive ﬁndings
were more likely to be cited in the reviews of which
we examined, and as they are more likely to form
part of the title of the paper which we based our initial
search on. We did not formally evaluate the quality of
the included studies as the results were overall weak.
A second drawback of the review is the fact that we
excluded studies that investigated the effect of psycho-
therapy on relapse risk after antidepressant discontinu-
ation as this would have confounded the ﬁndings
given that psychotherapy is known to be effective in
preventing relapses (e.g. Hollon et al. 2005). In this
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vein, however, we would like to emphasize that we
consider it highly important that patients are informed
about alternative treatments, particularly psychothera-
peutic ones. Although, as mentioned previously, the
presented results might be subject to a positive bias
in respect to the reported literature and results of
data analyses, the presented view might be overly
negative concerning the underlying effect. This prob-
ably results from the small sample sizes of the studies
mentioned, making the discovery of signiﬁcant results
less probable. Since, in total, sufﬁcient data have been
collected, rather than conducting a further medium-
sized trial, we recommend the reanalysis of concate-
nated raw data from previous trials using a machine
learning approach, similar to, for example, Chekroud
et al. (2016). In fact, we are planning to conduct such
a mega-analysis, i.e. reanalysing the raw data of a
range of identiﬁed datasets to investigate relapse pre-
dictors after antidepressant discontinuation.
Conclusion
Maintenance treatment after a remission from depres-
sion, particularly after multiple episodes, is the stand-
ard of care. However, it is not a panacea. Patients
discontinue for a variety of reasons including side
effects; and there are indications that tachyphylaxis
(Rothschild et al. 2009) and even oppositional tolerance
may occur (Andrews et al. 2011; El-Mallakh & Briscoe,
2012). Individual patients must be provided with good
information about the likely course of their own dis-
ease trajectory to allow them and their physicians to
make informed choices. As we have seen here, few of
the predictors of overall relapse risk, surprisingly, ap-
pear to differentially predict relapses after continuation
v. discontinuation. On the one hand, this is clearly due
to the scarcity of studies that have attended to the
problem. On the other hand, the strong effects on re-
lapse rates of both antidepressants and predictors
would have rendered strong interaction effects a dis-
tinct possibility. It is hence critical to revisit the existing
datasets to re-examine this problem. In doing so, the
ﬁeld can now avail itself of novel techniques both
from machine learning and computational psychiatry
(Huys et al. 2011; Montague et al. 2012; Wolfers et al.
2015; Chekroud et al. 2016) to hopefully provide indi-
vidually valid predictors of differential risk.
Finally, the list of predictors evaluated so far
includes no neurobiological assessments. This should
be addressed as such measurements hold great prom-
ise in predicting individual outcomes. Farb et al. (2011),
for instance, found that a simple functional magnetic
resonance imaging (fMRI) measure coupled with an
emotion manipulation (sad movies) could near perfect-
ly predict relapse overall independently of treatment,
and Lythe et al. (2015) found that self-blame-related
fMRI connectivity features had predictive validity.
Other neurobiological features might relate to speciﬁc
treatments. Clearly, advances in neuroimaging and
the neurosciences more generally should be brought
to bear on this pressing clinical issue.
Acknowledgements
This research was funded by a Swiss National Science
Foundation project grant to Q.J.M.H. (320030L_153449/1).
H.W. is supported by a grant from the Deutsche
Forschungsgesellschaft (WA 1539/5-1). We thank Eric
Ruhe and Joshua Buckman for helpful discussions.
Declaration of Interest
None.
References
American Psychiatric Association (2000). Diagnostic and
Statistical Manual Text Revision (DSM-IV-TR). American
Psychiatric Association: Washington, DC.
Andrews PW, Kornstein SG, Halberstadt LJ, Gardner CO,
Neale MC (2011). Blue again: perturbational effects of
antidepressants suggest monoaminergic homeostasis in
major depression. Frontiers in Psychology 2, 159.
Baldessarini RJ, Lau WK, Sim J, Sum MY, Sim K (2015).
Duration of initial antidepressant treatment and subsequent
relapse of major depression. Journal of Clinical
Psychopharmacology 35, 75–76.
Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J,
Möller H-J (2013). World Federation of Societies of
Biological Psychiatry (WFSBP) guidelines for biological
treatment of unipolar depressive disorders, part 1: update
2013 on the acute and continuation treatment of unipolar
depressive disorders. World Journal of Biological Psychiatry
14, 334–385.
Berlanga C, Heinze G, Torres M, Apiquián R, Caballero A
(1999). Personality and clinical predictors of recurrence of
depression. Psychiatric Services 50, 376–380.
Burcusa SL, Iacono WG (2007). Risk for recurrence in
depression. Clinical Psychology Review 27, 959–985.
Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R,
Johnson MK, Trivedi MH, Cannon TD, Krystal JH,
Corlett PR (2016). Cross-trial prediction of treatment
outcome in depression: a machine learning approach.
Lancet Psychiatry 3, 243–250.
Dunlop BW, Holland P, Bao W, Ninan PT, Keller MB (2012).
Recovery and subsequent recurrence in patients with
recurrent major depressive disorder. Journal of Psychiatric
Research 46, 708–715.
El-Mallakh PRS, Briscoe B (2012). Studies of long-term use of
antidepressants. CNS Drugs 26, 97–109.
Farb NAS, Anderson AK, Bloch RT, Segal ZV (2011).
Mood-linked responses in medial prefrontal cortex predict
Predicting relapse after antidepressant withdrawal 435
https://doi.org/10.1017/S0033291716002580
Downloaded from https:/www.cambridge.org/core. ETH-Bibliothek, on 24 Feb 2017 at 10:30:28, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
relapse in patients with recurrent unipolar depression.
Biological Psychiatry 70, 366–372.
Fava M, Wiltse C, Walker D, Brecht S, Chen A, Perahia D
(2009). Predictors of relapse in a study of duloxetine
treatment in patients with major depressive disorder.
Journal of Affective Disorders 113, 263–271.
Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori
PW, Rush AJ, Weissman MM (1991). Conceptualization
and rationale for consensus deﬁnitions of terms in major
depressive disorder: remission, recovery, relapse, and
recurrence. Archives of General Psychiatry 48, 851–855.
Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ,
Frank E, Goodwin GM (2003). Relapse prevention with
antidepressant drug treatment in depressive disorders: a
systematic review. Lancet 361, 653–661.
Glue P, Donovan MR, Kolluri S, Emir B (2010).
Meta-analysis of relapse prevention antidepressant trials in
depressive disorders. Australian and New Zealand Journal of
Psychiatry 44, 697–705.
Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman
ATF (2010). Prevalence and predictors of recurrence of
major depressive disorder in the adult population. Acta
Psychiatrica Scandinavica 122, 184–191.
Hochstrasser B, Isaksen PM, Koponen H, Lauritzen L,
Mahnert FA, Rouillon F, Wade AG, Andersen M,
Pedersen SF, Swart JCGD, Nil R (2001). Prophylactic effect
of citalopram in unipolar, recurrent depression. British
Journal of Psychiatry 178, 304–310.
Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD,
Salomon RM, O’Reardon JP, Lovett ML, Young PR, Haman
KL, Freeman BB, Gallop R (2005). Prevention of relapse
following cognitive therapy vs medications in moderate to
severe depression. Archives of General Psychiatry 62, 417–422.
Hunot VM, Horne R, Leese MN, Churchill RC (2007). A
cohort study of adherence to antidepressants in primary
care: the inﬂuence of antidepressant concerns and treatment
preferences. Primary Care Companion to the Journal of Clinical
Psychiatry 9, 91–99.
Huys QJM, Moutoussis M, Williams J (2011). Are
computational models of any use to psychiatry? Neural
Networks 24, 544–551.
Iovieno N, van Nieuwenhuizen A, Clain A, Baer L,
Nierenberg AA (2011). Residual symptoms after remission
of major depressive disorder with ﬂuoxetine and risk of
relapse. Depression and Anxiety 28, 137–144.
Joliat MJ, Schmidt ME, Fava M, Zhang S, Michelson D,
Trapp NJ, Miner CM (2004). Long-term treatment
outcomes of depression with associated anxiety: efﬁcacy of
continuation treatment with ﬂuoxetine. Journal of Clinical
Psychiatry 65, 373–378.
Kaymaz N, van Os J, Loonen AJM, Nolen WA (2008).
Evidence that patients with single versus recurrent
depressive episodes are differentially sensitive to treatment
discontinuation: a meta-analysis of placebo-controlled
randomized trials. Journal of Clinical Psychiatry 69, 1423–1436.
Keller MB, Kocsis JH, Thase ME, Gelenberg AJ, Rush AJ,
Koran L, Schatzberg A, Russell J, Hirschfeld R, Klein D,
Mccullough JP, Fawcett JA, Kornstein S, Lavange L,
Harrison W (1998). Maintenance phase efﬁcacy of sertraline
for chronic depression: a randomized controlled trial.
Journal of the American Medical Association 280, 1665–1672.
Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein
SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH,
Dunner DL, Hirschfeld RMA, Rothschild AJ, Ferguson
JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B,
Ahmed S, Musgnung J, Ninan PT (2007). The Prevention
of Recurrent Episodes of Depression with Venlafaxine for
Two Years (PREVENT) study: outcomes from the 2-year
and combined maintenance phases. Journal of Clinical
Psychiatry 68, 1246–1256.
Kendler KS, Thornton LM, Gardner CO (2000). Stressful life
events and previous episodes in the etiology of major
depression in women: an evaluation of the “Kindling”
hypothesis. American Journal of Psychiatry 157, 1243–1251.
Kessler RC, Berglund P, Demler O, Jin R, Koretz D,
Merikangas KR, Rush AJ, Walters EE, Wang PS; National
comorbidity survey Replication (2003). The epidemiology
of major depressive disorder: results from the National
Comorbidity Survey Replication (NCS-R). Journal of the
American Medical Association 289, 3095–3105.
Khan A, Bhat A, Kolts R, Thase ME, Brown W (2010). Why
has the antidepressant–placebo difference in antidepressant
clinical trials diminished over the past three decades? CNS
Neuroscience and Therapeutics 16, 217–226.
Kornstein SG, Pedersen RD, Holland PJ, Nemeroff CB,
Rothschild AJ, Thase ME, Trivedi MH, Ninan PT, Keller
MB (2014). Inﬂuence of sex and menopausal status on
response, remission, and recurrence in patients with
recurrent major depressive disorder treated with
venlafaxine extended release or ﬂuoxetine: analysis of data
from the PREVENT study. Journal of Clinical Psychiatry 75,
62–68.
Lythe KE, Moll J, Gethin JA, Workman CI, Green S,
Lambon Ralph MA, Deakin JF, Zahn R, (2015). Self-
blame–selective hyperconnectivity between anterior
temporal and subgenual cortices and prediction of
recurrent depressive episodes. JAMA Psychiatry 72,
1119–1126.
McGrath PJ, Stewart JW, Petkova E, Quitkin FM,
Amsterdam JD, Fawcett J, Reimherr FW, Rosenbaum JF,
Beasley CM (2000). Predictors of relapse during ﬂuoxetine
continuation or maintenance treatment of major depression.
Journal of Clinical Psychiatry 61, 518–524.
McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE,
Nierenberg AA, Fava M, Cheng J, Petkova E (2006).
Predictors of relapse in a prospective study of ﬂuoxetine
treatment of major depression. American Journal of
Psychiatry 163, 1542–1548.
Monroe SM, Harkness KL (2005). Life stress, the ‘Kindling’
hypothesis, and the recurrence of depression:
considerations from a life stress perspective. Psychological
Review 112, 417–445.
Monroe SM, Harkness KL (2011). Recurrence in major
depression: a conceptual analysis. Psychological Review 118,
655–674.
Montague PR, Dolan RJ, Friston KJ, Dayan P (2012).
Computational psychiatry. Trends in Cognitive Sciences 16,
72–80.
436 I. M. Berwian et al.
https://doi.org/10.1017/S0033291716002580
Downloaded from https:/www.cambridge.org/core. ETH-Bibliothek, on 24 Feb 2017 at 10:30:28, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
National Collaborating Centre for Mental Health (UK)
(2010). Depression: The Treatment and Management of
Depression in Adults (Updated Edition). National Institute for
Health and Clinical Excellence: Guidance. British
Psychological Society: Leicester, UK.
Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden
D, Wisniewski SR, Miyahara S, Rush AJ (2010). Residual
symptoms after remission of major depressive disorder
with citalopram and risk of relapse: a STAR*D report.
Psychological Medicine 40, 41–50.
Nierenberg AA, Quitkin FM, Kremer C, Keller MB, Thase
ME (2004). Placebo-controlled continuation treatment with
mirtazapine: acute pattern of response predicts relapse.
Neuropsychopharmacology 29, 1012–1018.
Olfson M, Marcus SC, Tedeschi M, Wan GJ (2006).
Continuity of antidepressant treatment for adults with
depression in the United States. American Journal of
Psychiatry 163, 101–108.
Palmer DM (2015). Biomarkers for antidepressant selection:
iSPOT-D Study. Current Behavioral Neuroscience Reports 2,
137–145.
Perahia DG, Gilaberte I, Wang F, Wiltse CG, Huckins SA,
Clemens JW, Montgomery SA, Montejo AL, Detke MJ
(2006). Duloxetine in the prevention of relapse of major
depressive disorder. British Journal of Psychiatry 188, 346–353.
Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW,
McGrath PJ, Harrison W (1987). Use of pattern analysis to
identify true drug response: a replication. Archives of General
Psychiatry 44, 259–264.
Rothschild AJ, Dunlop BW, Dunner DL, Friedman ES,
Gelenberg A, Holland P, Kocsis JH, Kornstein SG,
Shelton R, Trivedi MH, Zajecka JM, Goldstein C, Thase
ME, Pedersen R, Keller MB (2009). Assessing rates and
predictors of tachyphylaxis during the Prevention of
Recurrent Episodes of Depression with Venlafaxine ER for
Two Years (PREVENT) Study. Psychopharmacology Bulletin
42, 5–20.
Rouillon F, Berdeaux G, Bisserbe JC, Warner B, Mesbah M,
Smadja C, Chwalow J (2000). Prevention of recurrent
depressive episodes with milnacipran: consequences on
quality of life. Journal of Affective Disorders 58, 171–180.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA,
Stewart JW, Warden D, Niederehe G, Thase ME, Lavori
PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim
HA, Kupfer DJ, Luther J, Fava M (2006). Acute and
longer-term outcomes in depressed outpatients requiring
one or several treatment steps: a STAR*D report. American
Journal of Psychiatry 163, 1905–1917.
Schmidt ME, Fava M, Robinson JM, Judge R (2000). The
efﬁcacy and safety of a new enteric-coated formulation of
ﬂuoxetine given once weekly during the continuation
treatment of major depressive disorder. Journal of Clinical
Psychiatry 61, 851–857.
Sim K, Lau WK, Sim J, Sum MY, Baldessarini RJ (2015).
Prevention of relapse and recurrence in adults with major
depressive disorder: systematic review and meta-analyses
of controlled trials. International Journal of
Neuropsychopharmacology 19, pyv076.
Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava
M, Fawcett J, Reimherr F, Rosenbaum J, Beasley C,
Roback P (1998). Use of pattern analysis to predict
differential relapse of remitted patients with major
depression during 1 year of treatment with ﬂuoxetine or
placebo. Archives of General Psychiatry 55, 334–343.
Szegedi A, Jansen WT, Van Willigenburg APP, Van Der
Meulen E, Stassen HH, Thase ME (2009). Early
improvement in the ﬁrst 2 weeks as a predictor of treatment
outcome in patients with major depressive disorder : a
meta-analysis including 6562 patients. Journal of Clinical
Psychiatry 70, 344–353.
Thase ME, Nierenberg AA, Keller MB, Panagides J; Relapse
Prevention Study Group (2001). Efﬁcacy of mirtazapine for
prevention of depressive relapse: a placebo-controlled
double-blind trial of recently remitted high-risk patients.
Journal of Clinical Psychiatry 62, 782–788.
Trinh N-HT, Shyu I, McGrath PJ, Clain A, Baer L, Fava M,
Yeung A (2011). Examining the role of race and ethnicity in
relapse rates of major depressive disorder. Comprehensive
Psychiatry 52, 151–155.
Viguera AC, Baldessarini RJ, Friedberg J (1998).
Discontinuing antidepressant treatment in major
depression. Harvard Review of Psychiatry 5, 293–306.
Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ,
Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns
N, Burstein R, Murray CJ, Vos T (2013). Global burden of
disease attributable to mental and substance use disorders:
ﬁndings from the Global Burden of Disease Study 2010.
Lancet 382, 1575–1586.
Wolfers T, Buitelaar JK, Beckmann CF, Franke B, Marquand
AF (2015). From estimating activation locality to predicting
disorder: a review of pattern recognition for
neuroimaging-based psychiatric diagnostics. Neuroscience
and Biobehavioral Reviews 57, 328–349.
Yang H, Chuzi S, Sinicropi-Yao L, Johnson D, Chen Y, Clain
A, Baer L, McGrath PJ, Stewart JW, Fava M, Papakostas
GI (2009). Type of residual symptom and risk of relapse
during the continuation/maintenance phase treatment of
major depressive disorder with the selective serotonin
reuptake inhibitor ﬂuoxetine. European Archives of Psychiatry
and Clinical Neuroscience 260, 145–150.
Predicting relapse after antidepressant withdrawal 437
https://doi.org/10.1017/S0033291716002580
Downloaded from https:/www.cambridge.org/core. ETH-Bibliothek, on 24 Feb 2017 at 10:30:28, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
